Press releases

articles from July 2017

Orchard Therapeutics announces that OTL-101 has received a Rare Paediatric Disease Designation

The US Food and Drug Administration (FDA) granted a Rare Paediatric Disease Designation to OTL-101 for the treatment of adenosine deaminase severe combined immunodeficiency, commonly known as ADA-SCID or “bubble baby” disease

Read more